Nektar seeks U.S. approval for analgesic opioid molecule

Nektar Therapeutics (NASDAQ:NKTR) said it submitted an NDA to FDA for NKTR-181, an analgesic opioid molecule. Nektar said NKTR-181 is designed to have low blood brain barrier permeability to slow its rate of entry and reduce the release of dopamine, which causes the high levels of euphoria that lead to abuse and addiction with standard opioids.

The company declined to confirm the specific indication for which the NDA is seeking approval...